US Active Pharmaceutical Ingredient (API) Market by Type, Product and Application - Forecast and Analysis 2024-2028

1 Executive Summary

• 1.1 Market overview
  • Exhibit 01: Executive Summary – Chart on Market Overview
  • Exhibit 02: Executive Summary – Data Table on Market Overview
  • Exhibit 03: Executive Summary – Chart on Country Market Characteristics
  • Exhibit 04: Executive Summary – Chart on Market Segmentation by Type
  • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
  • Exhibit 07: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
  • Exhibit 08: Parent market
  • Exhibit 09: Market Characteristics

3 Market Sizing

• 3.1 Market definition
  • Exhibit 10: Offerings of vendors included in the market definition

• 3.2 Market segment analysis
  • Exhibit 11: Market segments

• 3.3 Market size 2023

• 3.4 Market outlook: Forecast for 2023-2028
  • Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%)
  • Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Active pharmaceutical ingredient (API) market in US 2018 - 2022
  • Exhibit 16: Historic Market Size – Data Table on active pharmaceutical ingredient (api) market in US 2018 - 2022 ($ billion)

• 4.2 Type Segment Analysis 2018 - 2022
  • Exhibit 17: Historic Market Size – Type Segment 2018 - 2022 ($ billion)

• 4.3 Product Segment Analysis 2018 - 2022
  • Exhibit 18: Historic Market Size – Product Segment 2018 - 2022 ($ billion)

• 4.4 Application Segment Analysis 2018 - 2022
  • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
  • Exhibit 20: Five forces analysis - Comparison between 2023 and 2028

• 5.2 Bargaining power of buyers
  • Exhibit 21: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028

• 5.3 Bargaining power of suppliers
  • Exhibit 22: Bargaining power of suppliers – Impact of key factors in 2023 and 2028

• 5.4 Threat of new entrants
  • Exhibit 23: Threat of new entrants – Impact of key factors in 2023 and 2028

• 5.5 Threat of substitutes
  • Exhibit 24: Threat of substitutes – Impact of key factors in 2023 and 2028

• 5.6 Threat of rivalry
  • Exhibit 25: Threat of rivalry – Impact of key factors in 2023 and 2028

• 5.7 Market condition
  • Exhibit 26: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

• 6.1 Market segments
  • Exhibit 27: Chart on Type - Market share 2023-2028 (%)
  • Exhibit 28: Data Table on Type - Market share 2023-2028 (%)

• 6.2 Comparison by Type
  • Exhibit 29: Chart on Comparison by Type
  • Exhibit 30: Data Table on Comparison by Type

• 6.3 Captive API - Market size and forecast 2023-2028
  • Exhibit 31: Chart on Captive API - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 32: Data Table on Captive API - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 33: Chart on Captive API - Year-over-year growth 2023-2028 (%)
  • Exhibit 34: Data Table on Captive API - Year-over-year growth 2023-2028 (%)

• 6.4 Contract API - Market size and forecast 2023-2028
  • Exhibit 35: Chart on Contract API - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 36: Data Table on Contract API - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 37: Chart on Contract API - Year-over-year growth 2023-2028 (%)
  • Exhibit 38: Data Table on Contract API - Year-over-year growth 2023-2028 (%)

• 6.5 Market opportunity by Type
  • Exhibit 39: Market opportunity by Type ($ billion)
  • Exhibit 40: Data Table on Market opportunity by Type ($ billion)

7 Market Segmentation by Product

• 7.1 Market segments
  • Exhibit 41: Chart on Product - Market share 2023-2028 (%)
  • Exhibit 42: Data Table on Product - Market share 2023-2028 (%)

• 7.2 Comparison by Product
  • Exhibit 43: Chart on Comparison by Product
  • Exhibit 44: Data Table on Comparison by Product

• 7.3 Generic - Market size and forecast 2023-2028
  • Exhibit 45: Chart on Generic - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 46: Data Table on Generic - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 47: Chart on Generic - Year-over-year growth 2023-2028 (%)
  • Exhibit 48: Data Table on Generic - Year-over-year growth 2023-2028 (%)

• 7.4 Innovative - Market size and forecast 2023-2028
  • Exhibit 49: Chart on Innovative - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 50: Data Table on Innovative - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 51: Chart on Innovative - Year-over-year growth 2023-2028 (%)
  • Exhibit 52: Data Table on Innovative - Year-over-year growth 2023-2028 (%)

• 7.5 Market opportunity by Product
  • Exhibit 53: Market opportunity by Product ($ billion)
  • Exhibit 54: Data Table on Market opportunity by Product ($ billion)

8 Market Segmentation by Application

• 8.1 Market segments
  • Exhibit 55: Chart on Application - Market share 2023-2028 (%)
  • Exhibit 56: Data Table on Application - Market share 2023-2028 (%)

• 8.2 Comparison by Application
  • Exhibit 57: Chart on Comparison by Application
  • Exhibit 58: Data Table on Comparison by Application

• 8.3 Oncology - Market size and forecast 2023-2028
  • Exhibit 59: Chart on Oncology - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 60: Data Table on Oncology - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 61: Chart on Oncology - Year-over-year growth 2023-2028 (%)
  • Exhibit 62: Data Table on Oncology - Year-over-year growth 2023-2028 (%)

• 8.4 Cardiovascular diseases - Market size and forecast 2023-2028
  • Exhibit 63: Chart on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 64: Data Table on Cardiovascular diseases - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 65: Chart on Cardiovascular diseases - Year-over-year growth 2023-2028 (%)
  • Exhibit 66: Data Table on Cardiovascular diseases - Year-over-year growth 2023-2028 (%)

• 8.5 Diabetes - Market size and forecast 2023-2028
  • Exhibit 67: Chart on Diabetes - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 68: Data Table on Diabetes - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 69: Chart on Diabetes - Year-over-year growth 2023-2028 (%)
  • Exhibit 70: Data Table on Diabetes - Year-over-year growth 2023-2028 (%)

• 8.6 Communicable diseases - Market size and forecast 2023-2028
  • Exhibit 71: Chart on Communicable diseases - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 72: Data Table on Communicable diseases - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 73: Chart on Communicable diseases - Year-over-year growth 2023-2028 (%)
  • Exhibit 74: Data Table on Communicable diseases - Year-over-year growth 2023-2028 (%)

• 8.7 Orthopedic and others - Market size and forecast 2023-2028
  • Exhibit 75: Chart on Orthopedic and others - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 76: Data Table on Orthopedic and others - Market size and forecast 2023-2028 ($ billion)
  • Exhibit 77: Chart on Orthopedic and others - Year-over-year growth 2023-2028 (%)
  • Exhibit 78: Data Table on Orthopedic and others - Year-over-year growth 2023-2028 (%)

• 8.8 Market opportunity by Application
  • Exhibit 79: Market opportunity by Application ($ billion)
  • Exhibit 80: Data Table on Market opportunity by Application ($ billion)

9 Customer Landscape

• 9.1 Customer landscape overview
  • Exhibit 81: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges
  • Exhibit 82: Impact of drivers and challenges in 2023 and 2028

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
  • Exhibit 83: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
  • Exhibit 84: Overview on factors of disruption

• 11.4 Industry risks
  • Exhibit 85: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
  • Exhibit 86: Vendors covered

• 12.2 Market positioning of vendors
  • Exhibit 87: Matrix on vendor position and classification

• 12.3 AbbVie Inc.
  • Exhibit 88: AbbVie Inc. - Overview
  • Exhibit 89: AbbVie Inc. - Product / Service
  • Exhibit 90: AbbVie Inc. - Key news
  • Exhibit 91: AbbVie Inc. - Key offerings

• 12.4 Amneal Pharmaceuticals Inc.
  • Exhibit 92: Amneal Pharmaceuticals Inc. - Overview
  • Exhibit 93: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 94: Amneal Pharmaceuticals Inc. - Key news
  • Exhibit 95: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 96: Amneal Pharmaceuticals Inc. - Segment focus

• 12.5 Aurobindo Pharma Ltd.
  • Exhibit 97: Aurobindo Pharma Ltd. - Overview
  • Exhibit 98: Aurobindo Pharma Ltd. - Product / Service
  • Exhibit 99: Aurobindo Pharma Ltd. - Key offerings

• 12.6 Cadila Pharmaceuticals Ltd.
  • Exhibit 100: Cadila Pharmaceuticals Ltd. - Overview
  • Exhibit 101: Cadila Pharmaceuticals Ltd. - Product / Service
  • Exhibit 102: Cadila Pharmaceuticals Ltd. - Key offerings

• 12.7 Cipla Ltd.
  • Exhibit 103: Cipla Ltd. - Overview
  • Exhibit 104: Cipla Ltd. - Business segments
  • Exhibit 105: Cipla Ltd. - Key news
  • Exhibit 106: Cipla Ltd. - Key offerings
  • Exhibit 107: Cipla Ltd. - Segment focus

• 12.8 Dr Reddys Laboratories Ltd.
  • Exhibit 108: Dr Reddys Laboratories Ltd. - Overview
  • Exhibit 109: Dr Reddys Laboratories Ltd. - Business segments
  • Exhibit 110: Dr Reddys Laboratories Ltd. - Key offerings
  • Exhibit 111: Dr Reddys Laboratories Ltd. - Segment focus

• 12.9 GlaxoSmithKline Plc
  • Exhibit 112: GlaxoSmithKline Plc - Overview
  • Exhibit 113: GlaxoSmithKline Plc - Business segments
  • Exhibit 114: GlaxoSmithKline Plc - Key news
  • Exhibit 115: GlaxoSmithKline Plc - Key offerings
  • Exhibit 116: GlaxoSmithKline Plc - Segment focus

• 12.10 Koninklijke DSM NV
  • Exhibit 117: Koninklijke DSM NV - Overview
  • Exhibit 118: Koninklijke DSM NV - Business segments
  • Exhibit 119: Koninklijke DSM NV - Key news
  • Exhibit 120: Koninklijke DSM NV - Key offerings
  • Exhibit 121: Koninklijke DSM NV - Segment focus

• 12.11 Lupin Ltd.
  • Exhibit 122: Lupin Ltd. - Overview
  • Exhibit 123: Lupin Ltd. - Product / Service
  • Exhibit 124: Lupin Ltd. - Key news
  • Exhibit 125: Lupin Ltd. - Key offerings

• 12.12 Novartis AG
  • Exhibit 126: Novartis AG - Overview
  • Exhibit 127: Novartis AG - Business segments
  • Exhibit 128: Novartis AG - Key offerings
  • Exhibit 129: Novartis AG - Segment focus

• 12.13 Pfizer Inc.
  • Exhibit 130: Pfizer Inc. - Overview
  • Exhibit 131: Pfizer Inc. - Product / Service
  • Exhibit 132: Pfizer Inc. - Key news
  • Exhibit 133: Pfizer Inc. - Key offerings

• 12.14 Sanofi SA
  • Exhibit 134: Sanofi SA - Overview
  • Exhibit 135: Sanofi SA - Business segments
  • Exhibit 136: Sanofi SA - Key news
  • Exhibit 137: Sanofi SA - Key offerings
  • Exhibit 138: Sanofi SA - Segment focus

• 12.15 Sun Pharmaceutical Industries Ltd.
  • Exhibit 139: Sun Pharmaceutical Industries Ltd. - Overview
  • Exhibit 140: Sun Pharmaceutical Industries Ltd. - Product / Service
  • Exhibit 141: Sun Pharmaceutical Industries Ltd. - Key news
  • Exhibit 142: Sun Pharmaceutical Industries Ltd. - Key offerings

• 12.16 Teva Pharmaceutical Industries Ltd.
  • Exhibit 143: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 144: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 145: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 146: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 147: Teva Pharmaceutical Industries Ltd. - Segment focus

• 12.17 Viatris Inc.
  • Exhibit 148: Viatris Inc. - Overview
  • Exhibit 149: Viatris Inc. - Business segments
  • Exhibit 150: Viatris Inc. - Key news
  • Exhibit 151: Viatris Inc. - Key offerings
  • Exhibit 152: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist
  • Exhibit 153: Inclusions checklist
  • Exhibit 154: Exclusions checklist

• 13.3 Currency conversion rates for US$
  • Exhibit 155: Currency conversion rates for US$

• 13.4 Research methodology
  • Exhibit 156: Research methodology
  • Exhibit 157: Validation techniques employed for market sizing
  • Exhibit 158: Information sources

• 13.5 List of abbreviations
  • Exhibit 159: List of abbreviations